A61K 47/67
Enzyme prodrug therapy
Official title: {Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT}
A61K47/67 (Enzyme prodrug therapy) appears on 73 US grants and 113 published applications in this corpus.
Search patents in A61K- Granted patents
- 73
- Published applications
- 113
- Assignees
- 76
- Inventors
- 205
- Latest grant
- 21 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 1 | 0 |
| 1998 | 0 | 0 |
| 1999 | 1 | 0 |
| 2000 | 3 | 0 |
| 2001 | 3 | 1 |
| 2002 | 2 | 3 |
| 2003 | 1 | 10 |
| 2004 | 1 | 10 |
| 2005 | 0 | 4 |
| 2006 | 3 | 12 |
| 2007 | 5 | 6 |
| 2008 | 4 | 9 |
| 2009 | 4 | 10 |
| 2010 | 8 | 4 |
| 2011 | 4 | 3 |
| 2012 | 4 | 4 |
| 2013 | 2 | 3 |
| 2014 | 3 | 3 |
| 2015 | 1 | 3 |
| 2016 | 7 | 6 |
| 2017 | 2 | 0 |
| 2018 | 3 | 6 |
| 2019 | 0 | 3 |
| 2020 | 7 | 1 |
| 2021 | 0 | 3 |
| 2022 | 2 | 2 |
| 2023 | 1 | 1 |
| 2024 | 0 | 4 |
| 2025 | 0 | 0 |
| 2026 | 1 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Protein-drug conjugates comprising camptothecin analogs and methods of use thereof21 Apr 2026US 12,605,459 B2Regeneron Pharmaceuticals, Inc.
- Peptide or pharmaceutically acceptable salt thereof, or prodrug thereof31 Jan 2023US 11,566,047 B2Tokyo University of Pharmacy & Life Sciences
- Nucleic acids encoding engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene8 Mar 2022US 11,266,693 B2Precision BioSciences, Inc.
- Skin treatment devices and methods with pre-stressed configurations15 Feb 2022US 11,246,763 B2The Board of Trustees of the Leland Stanford Junior University
- L-asparaginase variants and fusion proteins with reduced L-glutaminase activity and enhanced stability3 Nov 2020US 10,821,160 B2The Board of Trustees of the University of Illinois
- Protein-drug conjugates comprising camptothecin analogs and methods of use thereof10 Sep 2026US 2026/0263625 A1Regeneron Pharmaceutical, Inc.
- Cancer immunotherapies to promote hyperacute rejection2 Jul 2026US 2026/0183409 A1Cornell University
- Nucleic acids encoding engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene21 Nov 2024US 2024/0382526 A1Precision BioSciences, Inc.
- Protein-drug conjugates comprising camptothecin analogs and methods of use thereof1 Aug 2024US 2024/0252661 A1Regeneron Pharmaceuticals, Inc.
- Minimally toxic prodrugs18 Apr 2024US 2024/0123074 A1Cobiores NV
Most cited
By later US patents
- Elongated and multiple spacers in activatible prodrugs154US 7,223,837 B2Syntarga B.V. · 2007
- Devices and bandages for the treatment or prevention of scars and/or keloids and methods and kits therefor67US 7,683,234 B2The Board of Trustees of the Leland Stanford Junior University · 2010
- Enzyme activated self-immolative n-substituted nitrogen mustard prodrugs57US 7,235,585 B2Cancer Research Technology Limited · 2007
- Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis57US 7,414,107 B2Zealand Pharma A/S · 2008
- Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis49US 7,935,786 B2Zealand Pharma A/S · 2011